Article

Pharmacological inhibition of the ALK axis elicits therapeutic potential in Consensus Molecular Subtype 1 colon cancer patients

2020-10-08

Abstract excerpt

In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). In this work, we performed a meta-analysis of 1700 CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3d58b98e-198e-504a-9175-9e681652ab63
DOI: 10.1101/2020.10.07.307991

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacological inhibition of the ALK axis elicits therapeutic potential in Consensus Molecular Subtype 1 colon cancer patientsDOI 10.1101/2020.10.07.307991Read

The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancerSemantic proximity Read

The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.Semantic proximity Read

Multi‐omic characterization of consensus molecular subtype 1 ( CMS1 ) colorectal cancer with dampened immune response improves precision medicineSemantic proximity Read

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targetsSemantic proximity Read

Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumorsSemantic proximity Read

From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.Semantic proximity Read

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity Read

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell linesSemantic proximity Read

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials.Semantic proximity Read

Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biologySemantic proximity Read

Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo.Semantic proximity Read

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsSemantic proximity Read